AML Hub

🎥The AML Hub symposium, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice, was chaired by Gail Roboz and featured presentations by Roboz, Jorge Sierra, and Jorge Cortes. Catch up here: loom.ly/J9p9_v8 #AMLsm #MedEd

New publication 📝 Results from a pooled analysis of the M14‑387 and VIALE‑C trials, published in @BloodPortfolio, show complex karyotype predicts poor outcomes in patients with ND #AML receiving LDAC + venetoclax. Learn more about AML: bit.ly/3NSE3Vk #MedNews #MedEd

New publication 📝 Retrospective data, published in @Hemasphere_EHA, show LIT + Ven improved response rates, OS, RFS, and allo-HSCT eligibility vs LIT alone in adults with ND non‑CBF T‑AML (CRc: 58% vs 40%; p = 0.003). Learn more: bit.ly/4sc6L2A #AML #AMLsm #MedNews #MedEd

AML World Awareness Day is coming: April 21, 2026 Join Know AML and the global community as we unite to raise awareness of acute myeloid leukemia: bit.ly/473LK1C #KnowAML #AMLWorldAwarenessDay #Cancer #Leukemia #Leucemia

New publication 📝 Phase II results, published in @Haematologica, show decitabine priming with low-dose chemotherapy demonstrated a CR/CRi rate of 73.3% in pediatric patients with R/R AML, with a 3-year OS of 60.8%. Learn more about AML: bit.ly/40utOcM #AMLsm #MedNews #MedEd

New publication 📝 Results from an analysis of the HARMONY platform, published in @LeukemiaJnl, show MRG mutations were associated with shorter RFS (HR, 1.37) and OS (HR, 1.34) in FLT3‑ITD/NPM1-wildtype #AML. Learn more: bit.ly/4cK7Ael #AMLsm #MedNews #MedEd

New publication 📝 Results from a post hoc analysis of the phase III CLTR0310‑301 study, published in @BloodPortfolio, show CPX‑351 improved OS in patients with AML‑MR vs 7 + 3 chemotherapy (p = 0.037). Learn more about AML: bit.ly/46CpFXL #AMLsm #AML #MedNews #MedEd

New publication📝 Real-world data, published in @AjHematology, show improved CRc (aOR, 1.97), OS (aHR, 0.46), EFS (aHR, 0.49), and RFS (aHR, 0.47) with IC + midostaurin vs IC alone in adults aged ≥60 years with ND FLT3-mutated #AML (all p ≤ 0.002). Learn more: bit.ly/4b4vpuG #AMLsm #MedNews #MedEd

New publication 📝 Retrospective results, published in @Haematologica, demonstrate a refined, 4-tier genetic risk classification for patients with #AML undergoing allo-HSCT with MAC and PTCy-based treatment. Learn more: bit.ly/4tj1Wp3 #AMLsm #MedNews #MedEd

New publication 📝 Results from a retrospective study, published in @Haematologica, show IC and HMA + Ven demonstrate comparable CR/CRi (p = 0.20) and MRD-negativity (p = 0.77) rates in patients with #AML who have chromosome 5 and/or 7 abnormalities. Learn more about AML: bit.ly/4kUsE3H #AMLsm #MedNews #MedEd

📝 During the recent AML Hub virtual symposium closing Q&A session, Gail Roboz, Jorge Sierra and Jorge Cortes answered audience questions around treatment decisions for patients with FLT3m AML. Watch the full video here: bit.ly/4aIVAYS #AMLsm #leusm #MedEd

New publication📝A retrospective analysis, published in Annals of Hematology, shows low PRDM16 expression was independently associated with longer OS in NPM1-mutated/FLT3-ITD #AML (HR, 0.467; p = 0.006) vs intermediate/high PRDM16 expression. Learn more: bit.ly/3OtuEUk #AMLsm #MedNews #MedEd

🚨 News 🚨 @US_FDA has approved filgrastim-laha, a G-CSF biosimilar to filgrastim, for the treatment of neutropenia, including in patients with AML receiving induction or consolidation chemotherapy. Read more: prn.to/4kHs0Gs #AMLsm #leusm #MedNews #MedEd

🎙️ During the recent AML Hub virtual symposium’s Q&A session, Gail Roboz, Jorge Sierra, and Jorge Cortes discussed treatment decision-making for the management of FLT3-mutated acute myeloid leukemia. Listen here: bit.ly/4aimBlO #AMLsm #leusm #MedEd

New publication 📝 Sex-stratified analysis of the GIMEMA AML1310 trial, published in @AJHematology, shows female patients with NPM1-mutated #AML had superior 6-year OS vs male patients with NPM1 mutations (52.4% vs 33.8%; p = 0.032). Learn more: bit.ly/4tD3avH #AMLsm #MedNews #MedEd

📝 During the recent AML Hub virtual symposium, Gail Roboz discussed the management of AML with FLT3-ITD and -TKD mutations in clinical practice. Watch the full video here: bit.ly/4asf6Yv #AMLsm #leusm #MedEd

🎙️ During the recent AML Hub virtual symposium, Gail Roboz discussed the management of acute myeloid leukemia with FLT3-ITD and -TKD mutations in clinical practice. Listen here: bit.ly/4trCEVT #AMLsm #leusm #MedEd

New publication📝AMLSG 21-13 phase III results, published in @BloodPortfolio, show adding dasatinib to IC did not improve EFS in adults with CBF-AML (HR, 0.92; 95% CI, 0.63–1.33; p = 0.66), but increased toxicity. Learn more: bit.ly/4r8H1DX #AML #AMLsm #MedNews #MedEd

New publication 📝 Consensus guideline updates from ELN-DAVID, published in @BloodPortfolio, provide a comprehensive framework for MRD assessment in AML. Learn more: bit.ly/4rDjgn4 #AML #leusm #MedNews #MedEd

The AML Hub is your go-to open-access resource for credible, up-to-date medical education in #AcuteMyeloidLeukemia – designed for time-stretched HCPs. Discover more: bit.ly/4keAq8j #AMLsm #leusm

New publication📝Results from a single-center study, published in @BMTjournal, show Flu/Mel conditioning + Tac/Sir #GvHD prophylaxis in patients with #AML undergoing allo-HSCT achieved a 5-year OS rate of 55% (95% CI, 49–61%). Learn more: bit.ly/4tj1Wp3 #AMLsm #leusm #MedNews #MedEd